Infliximab biobetter - Mabtech/Sorrento

Drug Profile

Infliximab biobetter - Mabtech/Sorrento

Alternative Names: STI-002

Latest Information Update: 14 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mabtech
  • Developer Mabtech Limited
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Biobetters
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Rheumatoid arthritis

Most Recent Events

  • 11 Jan 2016 Efficacy data from a phase III trial in Rheumatoid arthritis released by Sorrento Therapeutics
  • 03 Aug 2015 Monoclonal antibody biobetter licensed to Sorrento Therapeutics in European Union, Japan and North America
  • 03 Aug 2015 Phase-III clinical trials in Rheumatoid arthritis in China before August 2015 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top